Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency

NCT05078879 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

4

Enrollment

NIH

Sponsor class

Conditions

Crohn's Disease
Glycogen Metabolism
Inflammatory Bowel Disease (IBD)

Interventions

DRUG: Empagliflozin

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)